Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2016 07:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. Reports Data Demonstrating That the Company's Candidate Treatment for Multiple Sclerosis, IRX4204, Promotes Repair of Damaged Myelin

SANTA ANA, CA--(Marketwired - Sep 16, 2016) - Io Therapeutics, Inc., today, reported data demonstrating that the company's experimental rexinoid nuclear receptor (RXR) agonist compound, IRX4204,...
August 03, 2015 08:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. Announces Sponsored Research Agreement With the National Multiple Sclerosis Society Fast Forward Program

SANTA ANA, CA--(Marketwired - Aug 3, 2015) - Io Therapeutics, Inc. announced today the receipt of funding from the National Multiple Sclerosis Society through Fast Forward to support further...
February 26, 2013 13:53 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. Announces Collaboration With The Michael J. Fox Foundation for Parkinson's Research for Evaluation of IRX4204 as a Potential Treatment for Parkinson's Disease

SANTA ANA, CA--(Marketwire - Feb 26, 2013) - Io Therapeutics, Inc. announced today the initiation of a collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to evaluate...
September 13, 2012 19:30 ET | Source: Io Therapeutics, Inc.

IRX4204 as a Potential Disease-Modifying Treatment for Alzheimer's Disease

SAN FRANCISCO, CA--(Marketwire - Sep 13, 2012) - Io Therapeutics, Inc. announced today the presentation of data from preclinical studies of its Retinoid X Receptor (RXR) agonist compound IRX4204 in...
October 06, 2011 11:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. Announces Initiation of Dosing in a Phase II Clinical Trial of IRX4204 in Patients With Advanced Prostate Cancer

SANTA ANA, CA--(Marketwire - Oct 6, 2011) - Io Therapeutics, Inc. announced today initiation of dosing in a phase II clinical trial with its experimental cancer therapeutic, IRX4204, in patients...